The pioneering work in developing immunotherapy targeting PD-1 and PD-L1 (13, 44–47) has led to the most important breakthrough in cancer therapy, with rapidly expanding indications of anti–PD-1/PD-L1 antibodies adopted for treatment of both hematological and nonhematological malignancies (48). This evidence concerns the gene PDCD1 and cancer.